The neurobiology of sexual behavior involves the interrelationships between sex steroids and neurotransmitters that result in both central nervous system (CNS) effects and effects in the genitalia. Tools such as positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) scanning can help determine what areas of the brain are activated under sexual stimulation. Our understanding of the role of various neurotransmitters, neurosteroids and other CNS-acting compounds is improving. The role of CNS-acting compounds such as dopamine agonists in the treatment of male sexual dysfunction is under active investigation. Melanocortins have CNS and peripheral roles in a wide variety of bodily functions. The melanocortin agonist bremelanotide appears to act in the CNS to promote erections in preclinical models, and may also stimulate behaviors that facilitate sexual activity beyond their erectogenic effects.
Introduction
The neurobiology of sexual behavior involves the interrelationships between sex steroids and neurotransmitters that result in both central nervous system (CNS) effects and effects in the genitalia. Despite the advances made over the past 20 years in male sexual dysfunction, we are just beginning to understand the incredibly intricate interplay between neurotransmitters and neurosteroids in the CNS and periphery as initiators and/or facilitators of the sexual response cycle.
When discussing male sexual response, three major areas are usually considered. The first is libido, or desire to engage in sexual behaviors. The second is the erectile response, which is the ultimate end-organ manifestation of sexual motivation and arousal. Although interrelated, one can have arousal without desire and vice versa. The third major area of male sexuality is disorders of orgasm and ejaculation; however, this will not be covered in this review.
Neuroanatomy of male sexual response
Sex and the brain Sexual arousal can now be studied with such sophisticated tools as PET (positron emission tomography) and fMRI (functional magnetic resonance imaging) scanning to determine what areas of the brain are activated under sexual stimulation. 1 Using these techniques, when sexually stimulated, the activation of the right subinsular/insula region including the claustrum has been demonstrated using both fMRI and PET scanning techniques. 2 Other brain regions that have been reported to be activated during visual sexual stimuli include the right middle gyrus, right temporal gyrus, left caudate and putamen, bilateral cingulate gyri, right sensimotor and pre-motor regions. 1 Other studies have shown activation of the cerebellum in response to visual erotic stimuli as well as viewing pictures of sexual partners. In addition, PET scan studies have shown differences in brain activation among men with normal compared with hypoactive sexual responses when viewing sexual stimuli of varying grades of intensity. 3 In men with hypoactive sexual desire disorder, prolonged activation of the medial orbitofrontal cortex, which is involved in general inhibition of motivation, was seen.
Men also appear to have different brain activation patterns than women in response to sexual stimuli. 4 In this study, men displayed greater activation of the hypothalamus and amygdala compared with women overall in response to visual stimuli. Women who reported increased sexual arousal after being presented the erotic visual stimuli showed similar activation of the hypothalamus and amygdala. This may explain why men have a greater sensitivity to visual sexual stimuli than women.
In the supraspinal area, studies in animals have identified the medial preoptic area (MPOA) and the paraventricular nucleus (PVN) of the hypothalamus and hippocampus as important centers for sexual function and penile erection. 5, 6 In particular, the MPOA appears to be critical for male sexual behavior in all vertebrate species. 7 The nuclei of hypothalamic neurons contain several neurotransmitters that may be involved in penile erection, although the precise role and sequence of their activity remains to be elucidated.
Neural innervation of the penis
Input from the brain is relayed through descending spinal pathways to the penis through lumbar sympathetic and sacral parasympathetic outflows. 8 Basal antierectile tone in the flaccid state is mediated by sympathetic innervation of the pelvis, issuing from spinal segments T11 to L2. 9 The dorsolumbar spinal cord is the source of sympathetic pro-erectile pathways. 10 Preganglionic sympathetic fibers reach the penis via the lumbar splanchnic nerves or the paravertebral sympathetic chain, which relay ganglionic neurons in the hypogastric plexus or in the paravertebral sympathetic chain ganglia. Sympathetic postganglionic axons reach the penis through the hypogastric nerve, the paravertebral sympathetic chain and the paravertebral sympathetic chain via the pudendal nerve to the penis (Figure 1 ). Axons from preganglionic parasympathetic neurons emanate from sacral parasympathetic nuclei, establishing synapses in the pelvic plexus via the pelvic nerve.
Parasympathetic postganglionic fibers reach the penis via the cavernous nerve. Penile erection is seen when sacral cord, sacral roots, sacral nerves, the pelvic nerve or the cavernous nerve is stimulated.
Neurobiology of sexual response
The central neurochemistry mediating sexual behaviors include biogenic amines (dopamine, serotonin, noradrenaline and adrenaline) and peptides (oxytocin, prolactin and melanocortins) that affect the spinal network control of penile erection. 10 In addition, steroid hormones facilitate the sexual response process, most likely by facilitating changes in the release or effectiveness of one or more neurotransmitters. 7 Dopaminergic drugs have long been known to facilitate masculine sexual behavior. Although the D2 receptor family seems to be responsible for most of the behavioral effects of dopamine, D1 receptors also may play a role in sexual response. 11 Rodent studies have concluded that dopamine is involved in anticipatory rather than in consummatory motivational sexual responses. Quail models have proposed that dopamine activates a-2-noradrenergic receptors in the MPOA. 12 Peripheral dopamine D1 and D2 receptors have been identified in both rat and human seminal vesicles; however, the role of peripheral dopamine has not been established. 13 In a study of human volunteers, a single dose of levodopa facilitated somatic motor responses to sexual stimuli among men, but not women. 14 Parkinson disease patients treated with dopaminergic substances such as apomorphine, levodopa or bromocriptine report the occurrence of erections and increased libido or an improved sexual interest.
Serotonin appears to inhibit sexual function; however, this effect is most likely subtype specific. An increase in the concentration of the primary serotonin metabolite 5HIAA in the nucleus accumbens and the MPOA after ejaculation suggests that serotonin is involved in sexual satiety. 15 Inhibition of the 5-HT 2C receptor results in decreased sexual behavior in rats and retarded ejaculation in man, whereas 5-HT 1A inhibition does not produce similar effects. 16 However, 5-HT 1A receptor effects may depend upon location of the receptor in the brain as well as the level of activation (that is, dose effect). In rats, increasing serotonin by microinjection of selective serotonin reuptake inhibitor into the lateral hypothalamic area increased the latency time of onset of copulation as well as the latency to the first ejaculation. 7 Other CNS-acting peptides also play a role in sexual response. Prolactin influences the sexual excitement phase. 17 Hyperprolactinemia in men has been associated with a variety of effects, such as loss Figure 1 Extrinsic innervation of the male genital tract. B, bladder; CN, cavernous nerve; CP, celiac plexus; DPN, dorsal penile nerve; HN, hypogastric nerve; IMG, inferior mesenteric ganglion; ISN, inferior spermatic nerve; P, prostate; PN, pelvic nerve; PudN, pudendal nerve; SC, paravertebral sympathetic chain; SSN, superior spermatic nerve; SV, seminal vesicles; VD, vas deferens. L, lumbar; T, thoracic; and S, sacral segments of the spinal cord. 10 From Giuliano F et al. 10 with permission from Elsevier.
Effects of melanocortins in male sexual dysfunction AM Shadiack and S Althof of libido, erectile dysfunction, gynecomastia, reduced seminal volume and ejaculatory dysfunction. Dopamine lowers prolactin levels and dopaminergic agents are the treatment of choice for prolactinomas. 18 Oxytocin is present in the paraventricular and supraoptic nuclei of the hypothalamus. 19 Central oxytocinergic neurons project to other areas of the brain and the spinal cord, where they are thought to influence memory, learning, sexual behaviors-including penile erection and the postorgasmic feeling of sexual satiety-as well as behaviors such as social attachment and bonding. 20 The interaction between steroids and neurotransmitters in the CNS is still an area of active investigation. 21 Steroid hormones easily cross the blood-brain barrier, where extensive steroid metabolism occurs. Neurosteroids, whether originating from outside the CNS or synthesized de novo in the brain, modulate a wide range of neurotransmitters in the brain, including GABA (g-aminobutyric acid), NMDA (N-methyl-d-aspartate), and nicotinic, muscarinic, serotonin (5-HT 3 ), kainate, glycine and sigma receptors.
Nitric oxide (NO) is the primary signaling mechanism for penile erection. As reviewed elsewhere in this supplement, the endothelium of the penile vasculature is a major source of NO, and disturbances in endothelial function have been shown to be associated with erectile dysfunction of varying degrees of severity.
Neuronal NO also plays an important role in erectile function. nNOS (neuronal NO synthase) is found in cavernous nerves and their terminal endings within the corpora cavernosa, as well as in the nerve plexuses in the adventitia of the deep cavernous arteries and the branches of the dorsal penile nerves. 22 In the CNS, the PVN contains a significant amount of NOS. 16 Apomorphine and other dopamine agonists have been shown to increase NOS activity within oxytocinergic neurons in the PVN, and NO donors such as nitroglycerin or nitroprusside induce erections when injected into the PVN. NO also promotes the release of dopamine in the MPOA. Microinjection of an NOS inhibitor into the MPOA of sexually naive rats inhibited their ability to copulate, suggesting that NO may play both a central and a peripheral role in sexual response. 7 In the CNS, steroids such as androgens, estrogens and progestins interface with neurotransmitters, principally dopamine, to facilitate copulatory behaviors. 23 In both men and women, this interplay occurs simultaneously in the brain and periphery, changing the person's desire for sexual activity as well as enhancing physiological readiness for sex.
In rat studies, testosterone was found to promote increased dopamine release in the MPOA in response to the presence of a female behind a clear barrier. 24 Testosterone also appears to upregulate NOS activity in male rats. Increased NO production leads to an increased release of dopamine in both basal and sexual contexts, ultimately resulting in greater response to sexual stimuli.
Melanocortins
Melanocortins are a group of small protein molecules that share the same precursor molecule, POMC (proopiomelanocortin). 25 These peptides include ACTH (adrenocorticotropic hormone), the melanocyte-stimulating hormones (a-MSH, b-MSH and g-MSH), b-and g-lipotropin, and b-endorphin. In the CNS, melanocortins may act as neurohormones or neurotransmitters, regulating numerous functions within the neuronal systems in which they are synthesized and secreted. 26 It has been proposed that melanocortins, oxytocin and dopamine use a common pathway in the CNS that involves activation of NO to control erection. 27 Five melanocortin receptors have been identified that are associated with such diverse biological functions as skin pigmentation, food intake, the sleep-wake cycle and sexual response. Investigations into the role of the melanocortin system on sexual response has focused on the melanocortin 3 (MC3R) and melanocortin 4 (MC4R) receptors in the CNS. There is abundant expression of both MC3R and MC4R in the brain and in peripheral genital sensory outputs (Figure 2) . 27 However, MC4R has been shown to modulate erectile function and sexual behavior, whereas MC3R has not been shown to have a pro-erectile effect. 28 MC4R is expressed in the rat and human penis, as well as in rat spinal cord, hypothalamus, brainstem and pelvic ganglion, but not in rat corpus cavernosal smooth muscle cells. In mice, administration of an MC4R agonist increased copulation, whereas knockout mice lacking the gene encoding for the receptor showed decreased copulatory behavior.
Melanocortins and erection
Preclinical work conducted indicate that melanocortins promote erection primarily through activity in the CNS. Both ACTH and a-MSH injected into the hypothalamic periventricular region of the third ventricle of male rats resulted in increased levels of penile erection, as well as stretching, yawning and grooming. 29 However, neither caused those effects when injected into the preoptic area, the caudate nucleus or the CA1 field of the hippocampus.
In a different rat model, 10 min after intracerebroventricular administration of a-MSH, there was a 10-fold increase in the frequency of penile erections. 30 Increases in erection frequencies were seen by injecting both ACTH and a-MSH directly into PVN of the hypothalamus. Blocking the MC4R with HS014, a non-selective MC4R antagonist, did not alter these responses.
Melanotan-II (MT-II), a cyclic heptapeptide containing amino acids representing the core melanocortin receptor-binding region, had no effect on strips of penile tissue from rabbits subjected to an electrical field, but intravenous injections resulted in increased cavernosal pressures. 31 The effects of MT-II were abolished by severing the pudendal nerve or by administering L-NAME (NGnitro-L-arginine methyl ester), an inhibitor of NOS. The data suggest that MT-II effects on erection are cause by activation of central melanocortin receptors resulting in neuronal release of NO. Intrathecal delivery of MT-II to the lumbosacral spinal cord of anesthetized rats was more efficacious in inducing erections than intracerebroventricular or intravenous administration. 32 These investigations were among the first to show distal spinal cord involvement in the pro-erectile function of melanocortins.
Bremelanotide preclinical investigations
Bremelanotide (formerly known as PT-141) is a synthetic analogue of a-MSH, which is an agonist of the MC4R. 33 Bremelanotide shows about double the affinity for the MC4R as for the MC3R in cells containing cloned human melanocortin receptors.
In preclinical experiments, central doses of bremelanotide delivered into the right lateral ventricle show consistent initiation of spontaneous penile erections in adult male rats (Figure 3) . 34 In addition, administration of bremelanotide either intravenously or intranasally also resulted in spontaneous erections. The frequency of erections increased in a dose-dependent manner (Figure 4 ). In addition, with repeat doses of bremelanotide, spontaneous erections continue to be produced without evidence of tachyphylaxis. Repeat dosing also results in a reduction in the time to first erection (latency). Administering L-NAME (an inhibitor of NOS) blocked the pro-erectile effects of bremelanotide, suggesting that NO is involved in this mechanism ( Figure 5) .
To assess the degree of the extent and distribution of neuronal activation, a c-Fos immunoreactivity assay was used. 33 Immunoreactivity after systemic administration of efficacious doses of bremelanotide was seen in the PVN and the supraoptic nucleus of the hypothalamus. In addition, an experiment using pseudorabies virus injected into the corpora cavernosa was used to determine associations between the hypothalamus and nerve endings in the penis associated with the erectogenic activity of bremelanotide. Pseudorabies virus was detected in the PVN after a 4-or 5-day wait for retrograde trans-synaptic transport of the virus to the spinal cord and then the brain. The neuronal activation studies and the pseudorabies experiment suggest that bremelanotide acts in the hypothalamus by activating MC3R and/or MC4R.
Preclinical experiments in female rats suggest that bremelanotide may not merely be pro-erectile as in MeA, medial amygdala; MPOA, medial preoptic area; PAG, periaqueductal gray; PVN, paraventricular nucleus; SPN, sympathetic preganglionic neurons; NPGI, nucleus paragigantocellularis. 27 From Giuliano F 27 with permission from the Journal of Andrology.
Effects of melanocortins in male sexual dysfunction AM Shadiack and S Althof S14 male rats, but may also facilitate behavioral changes that support sexual activity. 35 Female rats who were given bremelanotide exhibited behaviors associated with increased proceptivity or motivation to copulation compared with those given a placebo. In this experiment, the rats were placed in specially designed cages where the female rat was allowed to set the pace of sexual activity. It was up to the female rats to initiate sexual contact with the male rats. The increase in proceptive or solicitation behaviors was not due to any general stimulatory effect of bremelanotide or accompanied by an effect on receptive behaviors such as lordosis.
Discussion
The efficacy of CNS-acting agents in the treatment of male sexual dysfunction remains to be proven. In this supplement, a review of clinical trial data available to date on various agents will be presented by Hellstrom. However, preclinical investigations seem to indicate that CNS-acting agents may provide new options for patients suffering from various forms of sexual dysfunctions. If proven in clinical research, such agents may give us options for treatment of those with sexual desire or arousal disorders that are not amenable to therapy with erectogenic agents that work primarily in the vasculature, such as the PDE-5 inhibitors or the prostacyclins. CNS-acting agents may also provide additional pathways that will facilitate or augment other treatment modalities.
Finally, CNS-acting agents may prove to be not merely erectogenic in men, but also improve perceptions of psychological pro-sexual correlates such as vitality and youthfulness. As our current treatment options for loss of libido or hypoactive sexual desire disorder in men are inadequate, this research provides new directions that may result in greater improvements in our ability to deal with a much wider range of male sexual dysfunction. Nitric oxide synthase (NOS) inhibitor NG-nitro-L-arginine methyl ester (L-NAME) reduces mean number of erections per rat following dosing with bremelanotide. Eight animals per group were dosed intravenously with 100 ml of saline or L-NAME followed immediately by 100 ml of saline or 3 mg kg À1 bremelanotide. 34 PE, penile erection.
